Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
Meixi Hao, Siyuan Hou, Weishuo Li, Kaiming Li, Lingjing Xue, Qifan Hu, Lulu Zhu, Yue Chen, Hongbin Sun, Caoyun Ju, Can Zhang
Abstract
T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.
Topics & Concepts
ImmunotherapyReprogrammingSolid tumorMedicineCombination therapyCancer researchCell therapyCellImmunologyInternal medicineImmune systemBiologyCancerBiochemistryCAR-T cell therapy researchCancer Research and TreatmentsNeuroblastoma Research and Treatments